Apogee Therapeutics, Inc Common Stock

Yahoo Finance • 2 months ago

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results

Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule; topline Part A 16-week data expected mid-2025 APG279 (APG777 + APG990) Phase 1b head-to-head study vs. DUPI... Full story

Yahoo Finance • 2 months ago

Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)

Interim Phase 1 results for APG990, a novel half-life extended OX40L antibody, exceeded trial objectives and demonstrated an approximately 60-day half-life APG279 (APG777 + APG990) Phase 1b head-to-head study vs. DUPIXENT supported by suc... Full story

Yahoo Finance • 2 months ago

Is Apogee Therapeutics, Inc. (APGE) the Best Small-Cap Stock to Buy Now?

We recently published a list of the 10 Best Small-Cap Stocks to Buy Now. In this article, we are going to take a look at where Apogee Therapeutics, Inc. (NASDAQ:APGE) stands against the other small-cap stocks. The S&P 500 index has reache... Full story

Yahoo Finance • 2 months ago

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025

SAN FRANCISCO and BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest... Full story

Yahoo Finance • 2 months ago

Apogee Therapeutics to Participate in Upcoming March Investor Conferences

SAN FRANCISCO and BOSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE) today announced that members of management will participate at the following investor conferences. TD Cowen 45th Annual Health Care Co... Full story

Yahoo Finance • 3 months ago

Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolled Part A 16-week proof-of-concept data anticipated in mid-2025 SAN FRANCISCO and BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Apogee... Full story

Yahoo Finance • 3 months ago

Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference

SAN FRANCISCO and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Wednes... Full story

Yahoo Finance • 9 months ago

Apogee Therapeutics Inc (APGE) CEO Michael Henderson Sells 40,000 Shares

Michael Henderson, the CEO of Apogee Therapeutics Inc (NASDAQ:APGE), sold 40,000 shares of the company on August 7, 2024. The transaction was disclosed in a recent SEC Filing. Following this sale, the insider now owns 1,434,487 shares of t... Full story

Yahoo Finance • last year

Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results

Phase 1 clinical trial of APG777, a fully optimized, subcutaneous, extended half-life anti-IL-13 antibody, initiated ahead of schedule with initial PK and safety data from healthy volunteers expected mid-2024; on track to begin Phase 2 in... Full story

Yahoo Finance • last year

Apogee Therapeutics to Participate in Upcoming November Investor Conferences

SAN FRANCISCO and WALTHAM, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, asthma, chron... Full story

Yahoo Finance • 2 years ago

Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress

SAN FRANCISCO, CA and WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), ast... Full story

Yahoo Finance • 2 years ago

Apogee Therapeutics to Participate at the 2023 Stifel Virtual I&I Day

SAN FRANCISCO and WALTHAM, Mass., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), chronic... Full story

Yahoo Finance • 2 years ago

Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results

$345 million in gross proceeds raised in upsized IPO, providing a projected operating runway into 4Q 2026 Phase 1 clinical trial initiated and first participant dosed ahead of schedule for lead product candidate, APG777, a fully optimized... Full story

Yahoo Finance • 2 years ago

Apogee Therapeutics Appoints Mark C. McKenna, Healthcare Veteran and Former Chairman, President and CEO of Prometheus Biosciences, as Chairman of its Board

SAN FRANCISCO and WALTHAM, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), chronic... Full story